CD63 and cancer: Furthermore, clinical studies recently have displayed an increasing amount of circulating EVs in patients with late‐stage cancer, which were corresponded with disease progression to a certain extent.28, 29, 30 Here, we demonstrated that the expression of CD63, which is a marker of EV formation, was associated with a poor prognosis in NPC patients.